1. Introduction {#section0005}
===============

A number of RNA-based vector systems have been used in the construction of HIV-1 and SIV vaccines. These include vectors based on negative strand RNA viruses [@bib1], [@bib2], [@bib3], positive strand RNA viruses such as Sendai virus [@bib4], coronavirus [@bib5] and lentiviruses [@bib6], and positive strand RNA replicon-based vectors derived from alphaviruses [@bib7], [@bib8], [@bib9], picornaviruses [@bib10], and flaviviruses [@bib11]. Replicon-based vectors exploit the ability of viral non-structural proteins to amplify greatly (in the cytoplasm of infected/transfected cells) the replicon RNA, which encodes both the heterologous protein and the viral non-structural proteins. This results in high-level expression of antigens and provides potent adjuvant activity via double-stranded RNA replication intermediates [@bib12]. We have previously described a replicon vector system based on the Kunjin virus [@bib12], a largely non-pathogenic flavivirus found in northern Australia [@bib13]. Kunjin replicon RNA can be packaged into virus-like particles (VLPs) using a packaging cell line expressing Kunjin structural proteins *in trans* [@bib14]. The resulting VLP vaccines are capable of inducing potent, long-lived and protective CD8 T cell responses in several murine systems [@bib12], [@bib15]. Kunjin replicon VLP vaccines encoding HIV-1 *gag* have also been shown to induce CD8 T cell immunity comparable to that seen after immunisation with recombinant vaccinia [@bib11]. In contrast to most alphavirus replicon-infected cells, Kunjin replicon-infected cells (i) do not show overt cytopathic effects, so both double strand RNA-induced "danger signals" and antigen production are maintained for extended periods and (ii) do not produce replication-competent viruses via recombination during VLP manufacture, with recombination in flavivirus systems appearing to be extremely low [@bib12].

The evaluation of SIV vaccines in non-human primates has proved to be an invaluable and enduring model system for testing new concepts in HIV vaccine development [@bib16], [@bib17], [@bib18], [@bib19]. Most SIV and HIV subunit vaccines encode *gag*, as Gag proteins are believed to be an important target of protective cellular immunity [@bib20], [@bib21]. Herein we describe the construction and immunogenicity of four SIV *gag* (*pol*) Kunjin replicon VLP vaccines. The first encodes SIV *gag* using the wild-type nucleic acid sequence (WT). The second encodes SIV *gag* using an RNA-optimised nucleic acid sequence (DX). HIV and SIV *gag* contain RNA inhibitory sequence (INS) elements, which have been shown to act at several levels to inhibit gag expression; primarily via nuclear retention of RNA in the absence of the Rev protein. RNA-optimisation strategies, which remove these INS elements by changing the codon usage, result in significant increases in protein expression from DNA-based expression vectors [@bib22], and such RNA-optimised SIV *gag* vaccines have been used in a number of monkey trials [@bib23], [@bib24]. Inhibition of nuclear export of *gag* RNA by INS sequences is unlikely to be an issue for the exclusively cytoplasmic Kunjin replicon RNA, however, INS elements have also been reported to reduce RNA stability and translation [@bib25], [@bib26]. The third SIV *gag* Kunjin replicon VLP vaccine encodes a human codon-optimised SIV *gag* gene (OPT). Codon optimisation has been used extensively to improve recombinant antigen expression in a number of systems and the process involves altering the codon usage to the one most commonly utilized in a given species [@bib27], [@bib28]. The fourth vaccine encodes wild-type matrix and capsid from *gag*-linked in-frame to reverse transcriptase from *pol* (Gag-pol). This approach has been described previously for HIV Gag and removes from the *gag* gene sequences that encode proteins with potentially immunosuppressive properties, whilst retaining sequences frequently recognised by T cells [@bib29]. Although all four vaccines expressed Gag protein at comparable levels, they behaved quite differently in terms of immunogenicity, protection and insert stability.

2. Materials and methods {#sec1}
========================

2.1. Plasmids and construction of Kunjin SIV gag (pol) vaccines {#section0010}
---------------------------------------------------------------

The RNA-based Kunjin replicon vector C20UbHDVrep (SP6KUNrep1) [@bib30] was used to construct WT, DX and OPT vaccines, and SP6KUNrep6 [@bib15] was used to construct the Gag-pol vaccine. These two RNA-based Kunjin replicon vectors are the same, except SP6KUNrep6 has two copies of the foot and mouse virus 2A autoprotease, one upstream of MluI (replacing the ubiquitin gene) and another one downstream of the SnaBI cloning sites [@bib12]. The Kunjin SIV *gag* WT construct encodes SIV mac239 *gag* subcloned from p239SpSp5′ [@bib31] (catalogue \#829, NIH AIDS Research & Reference Reagent Program, Germantown, MD, USA) using AscI sites. The Kunjin SIV *gag* DX construct was generated by subcloning RNA-optimised SIV mac239 *gag* DX [@bib23], [@bib24] from pFB-SIVgag DX CTE Neo [@bib32] using AscI/SnaBI sites. Kunjin SIV*gag* OPT was constructed using AscI/SnaBI sites and p01-426 (catalogue \#9422, NIH AIDS Research & Reference Reagent Program), which encodes human codon-optimised SIVmac239 *gag*. The Kunjin SIVmac239 Gag-pol vaccine was constructed by separately PCR-amplifying matrix (MA)/nucleocapsid (NC) and reverse transcriptase (RT) genes from p239SpSp5′ plasmid (NIH AIDS Research & Reference Reagent Program) and joining at SacII. The fragment was then cloned into the Mlu I and SnaB I sites of SP6KUNrep6 vector. Construction of the HIV-1 *gag* vaccine has been described previously and was expressed from the SP6KUNrep1 vector [@bib11]. All *gag* constructs used in this study-encoded alanine in place of the initial glycine in Gag.

2.2. Production of virus-like particles (VLPs) and determination of their titre {#section0015}
-------------------------------------------------------------------------------

Kunjin replicon RNAs were transcribed *in vitro* using SP6 RNA polymerase and electroporated into tetKUNCprME BHK packaging cells as described previously [@bib14]. Briefly, RNA (20--30 μg) was electroporated into 3 × 10^6^ packaging cells in suspension and the cells were seeded into a 100-mm dish and incubated at 37 °C for 3--5 days and culture fluid collected at days 3--5. The titre of infectious VLPs in infectious units (IUs) was determined by infection of Vero cells with 10-fold serial dilutions of the culture fluid. At 30--40 h post-infection the cells were fixed with methanol/acetone (1:1, v/v) and analysed by immunofluorescence antibody staining using the 4G4 monoclonal anti-NS1 antibody [@bib33], [@bib34] and the 55-2F12 anti-SIV Gag monoclonal antibody (catalogue \# 1610, NIH AIDS Research & Reference Reagent Program) and the number of positive cells counted using Zeiss Axiophot 2 fluorescent microscope (Carl Zeiss Microimaging GmbH, Berlin, Germany).

2.3. Detection of SIV gag and Kunjin NS5 protein by western blot {#section0020}
----------------------------------------------------------------

Vero or BHK cells were infected with VLPs at MOI = 1 or electroporated with 5--10 μg of Kunjin SIV *gag* RNA constructs and cultured for 2 days in a 60-mm dish. The cells were lysed with RIPA buffer and cell debris was removed by centrifugation. The protein concentration for each sample was determined using the BioRad Protein assay (Biorad, Regents Park, NSW, Australia). Fifteen microgram of total cell protein was separated on a 12.5% gel by SDS-PAGE and transferred onto Hybond-P membrane (Amersham-Pharmacia Biotech, UK) using the Mini Trans Blot transfer tanks (Biorad, Regents Park, NSW, Australia) at 4 °C.

The HIS-tagged recombinant SIV mac239 and HIV-1 (clade B SF2/BH10) gag proteins were expressed from the pET28a+ plasmid (Merck Pty. Ltd., VIC, Australia) under control of T7-promoter in *Escherichia coli* C43(DE3) [@bib35] and purified using a Ni-agarose column. Gag proteins were detected using the 55-2F12 or the AG3.0 monoclonal antibody (catalogue \# 4121. NIH AIDS Research & Reference Reagent Program). Kunjin NS5 protein was detected by an anti-Kunjin NS5 monoclonal antibody (5H1.1) (Hall et al., in press). The secondary antibody was sheep anti-mouse-HRP (Chemicon, Melbourne, Australia). The proteins were visualised by the Western Lightning Chemiluminescence Reagent (PerkinElmer, Boston, MA, USA).

2.4. Deletion mutant analyses {#section0025}
-----------------------------

Vero cells were transfected with Kunjin SIV *gag* VLPs at MOI = 1 and were cultured for 72 h. Total RNA was collected using Trizol reagent (Invitrogen) and SuperScript III reverse transcriptase (Invitrogen) was used to produce cDNA. PCR primers that bind to C20 and E22 of the Kunjin replicon vector backbone were then used to amplify fragments from the cDNA using DyNAzyme EXT (Finnzyme, Diagnostics, Espoo, Finland); forward primer 5′ ggctgtcaatatgctaaaacg 3′, reverse primer 5′ tctttctctccgtgaacgtgcat 3′.

2.5. Vaccination of mice {#section0030}
------------------------

Female BALB/c (H-2^d^) mice (6--8 weeks) were supplied by the Animal Resources Centre (Perth, Western Australia). Mice were vaccinated with the Kunjin replicon SIV *gag* VLP vaccines WT, OPT, DX, or Gag-pol, the Kunjin HIV-1 *gag* VLP vaccine [@bib11] or control VLPs diluted in RPMI 1640 and 10^6^  IU injected by the intraperitoneal (i.p.) route in a final volume of 200 μl.

2.6. ELISPOT assays {#section0035}
-------------------

Interferon γ (IFNγ) ELISPOT assays were conducted using 125 or 123 overlapping 15-mer peptides spanning the entire SIVmac239 or HIV-1 subtype B gag protein, respectively (catalogue \#6204 and 8117, respectively, NIH AIDS Research & Reference Reagent Program). The peptides were divided into six pools and the total final concentration of the peptide mix in each pool was 10 μg/ml. For Kunjin-specific responses directed to NS3, GYISTRVEL (H-2K^d^) was used (AusPep, Parkville Victoria, Australia). *Ex vivo* ELISPOT assays were conducted as described previously [@bib36] except that MultiScreen-IP hydrophobic PVDF membrane microtitre plates (Millipore Australia Ltd., North Ryde, Australia) and 25 IU/ml of IL-2 (kindly provided by Cetus Corp., Emeryville, CA, USA) was used. The highest cell concentration was 2.5 × 10^5^  cells/well in triplicate, followed by four doubling dilutions. Spots were counted using a KS ELISPOT reader (Carl Zeiss Vision GmbH, Hallbergmoos, Germany). Mean background spots from wells without peptide were subtracted from the mean number of spots obtained from wells with peptide.

Cultured ELISPOT assays were performed using splenocytes cultured *in vitro* for 6 days in 24 well plates (5 × 10^6^  cells/well in 1 ml medium) with a single pool of the entire overlapping gag peptides (10 μg/ml of the peptide pool) or GYISTRVEL (10 μg/ml). (Culture of splenocytes in the presence of 100 μg/ml of the SIV peptide pool resulted in excessive responses being detected in naïve mice---data not shown). On day 4 a further 1 ml of medium was added to each well. On day 6 the cells were used in the ELISPOT assay (as described above) starting at 1.25 × 10^5^  cells per well followed by four doubling dilutions.

Groups (*n*  = 3 or 4) were compared (using the total peptide response for each mouse) with the non-parametric Median test and the Monte Carlo significance given (SPPS for Windows, Version 15.0, 2007, SPSS Inc., Chicago, IL, USA).

2.7. Challenge assay using A20 cells expressing SIV gag {#section0040}
-------------------------------------------------------

A plasmid encoding an EGFP-SIV gag DX fusion protein was generated by subcloning human RNA-optimised SIV *gag* DX from the plasmid pCMVSIV*gag*DX [@bib24] (provided by Dr B. Felber) into XhoI/EcoRI sites of the pEGFP C3 plasmid (catalogue \#6082-1. BD Biosciences, Franklin Lakes, NJ, USA) to generate pEGFP SIV*gag*DX. This plasmid was used to transfect the BALB/c-derived A20 murine lymphoblastic leukemia cells (ATCC, TIB-208) using the GeneJammer Transfection Reagent (StrataGene, La Jolla, CA, USA). Cells were cultured for 24 h and sorted using MoFlo High-Performance Cell Sorter (Dako, Glostrup, Denmark) for high EGFP expression. The sorted cells were cultured in medium [@bib37] containing G418 (800 μg/ml) for 1--2 weeks then sorted again for high EGFP expression. This procedure was repeated eight times at which point expression had stabilised with \>95% of cells expressing EGFP as assessed by FACS after a week of culture under G418 selection. Expression of EGFP-SIV Gag DX fusion protein was also confirmed by western blot using anti-SIV Gag (55-2F12) and anti-EGFP antibodies (Molecular Probes, Leiden, Netherlands). (We were unable to generate a Gag-expressing line using J774 macrophage cells).

Groups of BALB/c mice were vaccinated twice separated by 2--3 weeks with 10^6^  IU of the four different VLPs encoding SIV mac239 *gag*, control VLPs, or RPMI 1640 by the i.p. route. Approximately 9 months after the last immunisation mice were challenged with the A20-EGFP-SIV*gag* cells (2.5 × 10^6^  cells/mouse) on the back by the subcutaneous route. Hair around the injection site was removed with an electric shaver prior to the challenge to facilitate injection and measurement of tumours. The tumour sizes were measured three times a week and mice were sacrificed when the tumour area reached 100 mm^2^. Differences between Kaplan--Meier survival curves were calculated using the log-rank test (SPSS for Windows).

3. Results {#section0045}
==========

3.1. Construction of Kunjin replicon vaccines expressing SIV gag {#section0050}
----------------------------------------------------------------

Four different Kunjin replicon VLP vaccines encoding SIV mac239 *gag* were constructed; SIV*gag* WT (WT), SIV *gag* DX (DX), SIV *gag* OPT (OPT), and SIV *gag-pol* (Gag-pol) ([Fig. 1](#fig1){ref-type="fig"} ). WT encodes full-length wild-type SIV *gag*, DX and OPT encode RNA- and codon-optimised versions of the SIV *gag* gene, respectively, and Gag-pol encodes wild type matrix and capsid from *gag* connected in-frame with reverse transcriptase from *pol*. An HIV-1 *gag* construct encoding wild-type HIV *gag* was used as a positive control (see below) and has the same vector backbone as that shown in [Fig. 1](#fig1){ref-type="fig"} [@bib11].Fig. 1Schematic representation of RNA Kunjin replicon constructs encoding the SIV *gag* and *gag-pol* antigens. The Kunjin replicon RNA contained the SP6 RNA promoter, the 5′ and 3′ untranslated regions (UTR), the first 20 amino acids of the Kunjin core protein (C20), ubiquitin (Ub) to allow N-terminal cleavage by ubiquitin hydrolase, the SIV *gag* or *gag-pol* genes, the 2A autoprotease sequence of the foot and mouse disease virus (FMDV2A) to allow C-terminal cleavage, the last 22 amino acids of the Kunjin envelope protein (E22), the non-structural proteins (NS1-NS5) that are responsible for RNA replication, the anti-genomic sequence of the hepatitis *delta* virus ribozyme (HDVr) and the polyadenylation signal from simian virus 40 (pA) [@bib12]. The wild type vaccine construct (WT) contains the full-length native SIV mac239 *gag* gene. The DX and OPT constructs contain RNA- and codon-optimised versions of this gene, respectively, with the positions of the codon changes schematically represented by vertical lines below the gene box. DX sequence was provided by Dr. Felber and 6% of nucleotides have been changed. The OPT sequence is available from the AIDS Research and Reference Reagent Program web site (catalogue \#9422) and 25% of nucleotides have been changed. The Gag-pol construct contains wild-type matrix and capsid from *gag* and in-frame reverse transcriptase from *pol*. The gag-pol construct contained a second FMDV2A site in place of the Ub sequence at the N-terminus of *gag*.

*In vitro* transcribed RNA derived from each Kunjin replicon DNA construct was used to manufacture VLPs in packaging cells [@bib14]. Each VLP vaccine was used to infect Vero cells *in vitro* and western blotting experiments (using the anti-SIV gag 55-2F12 antibody) illustrated that each vaccine expressed a protein of the expected molecular weight ([Fig. 2](#fig2){ref-type="fig"}A). Similar data was produced when Kunjin RNA (rather than VLPs) was used to transfect BHK cells ([Fig. 2](#fig2){ref-type="fig"}B), indicating there was no major differences in expression between monkey and rodent cells. In these experiments no major improvements in protein expression levels were seen for DX or OPT vaccines despite RNA- and codon optimisation. (No *in vitro* SIV Gag particle formation was observed by electron microscopy for these vaccine---data not shown.)Fig. 2Analysis of SIV gag expression from the four different Kunjin SIV*gag* constructs. (A) Analysis of SIV Gag protein expression after infection of Vero cells with Kunjin VLPs. Cells were lysed after 48 h incubation and total cell lysates analysed by western blot using anti-Gag antibody (55-2F12). (B) As for A except that BHK cells were transfected with RNA for each of the vaccine constructs. (C) Comparison of SIV Gag and HIV Gag protein expression after infection of Vero cells as above with WT and HIV-1 VLPs using the AG3.0 antibody. (D) Comparison of the reactivity of AG3.0 in western analysis with serial dilutions of purified recombinant SIV Gag and recombinant HIV Gag proteins.

When the lysates from SIV *gag* and HIV-1 *gag* VLP-infected cells were initially compared side by side in western analyses using the AG3.0 antibody, we were surprised to find that the expression of SIV Gag appeared to be substantially lower ([Fig. 2](#fig2){ref-type="fig"}C). It emerged, however, that this antibody recognises the SIV mac239 Gag protein much less effectively than the HIV-1 Gag protein ([Fig. 2](#fig2){ref-type="fig"}D). SIV Gag expression was thus probably not in reality substantially lower than HIV Gag expression in these Kunjin replicon systems.

A more extensive analysis of a panel of antibodies used for detecting SIV Gag proteins also revealed some hitherto unpublished differences in reactivity with Gag proteins from different SIV strains using different techniques. We have shown the data in [Table 1](#tbl1){ref-type="table"} and have added published information for completeness. This information will hopefully allow others to identify more easily the appropriate antibody for future SIV Gag studies.Table 1Reactivity of anti-SIVgag antibodies in different settingsAb (NIH cat)AG3.0 (4121)55-2F12 (1610)KK59 (2320)KK64 (2321)183-H12-5C (3537)TechniqueWEIWEIWEIWEIWEISIVmac239+^c^+^c^+^d^ (poor)+^c,d^+^c^+^d^+ [@bib62]+^c^+ [@bib62]+^c^+ [@bib63]+^c^SIVmne+^a^−^a^+ [@bib64]SIVmac251+^b^−^b^−^b^+ [@bib65]HIV-1+^b^+ [@bib66]+ [@bib67]+ [@bib68]+ [@bib69][^4]

3.2. Gag-specific T cell induction by Kunjin replicon SIV gag vaccines {#section0055}
----------------------------------------------------------------------

To compare the immunogenicity of the Kunjin SIV *gag* vaccine constructs, BALB/c mice were immunised twice with 10^6^  IU of each of the four VLP vaccines. IU represents the titre of VLPs expressing Gag (see [Table 2](#tbl2){ref-type="table"} ), so each mouse received the same number of Kunjin VLPs encoding *gag*. Two negative control groups were included to account for non-specific responses, one group received no vaccination (control naïve) and the second was vaccinated with VLPs not encoding *gag* (control VLP). Immunisations with Kunjin VLPs encoding HIV-1 *gag* was also included. Ten weeks after the last immunisation splenocytes were assayed by *ex vivo* and cultured IFNγ ELISPOT assays using six pools of overlapping peptides spanning the entire SIV Gag protein or in the case of HIV *gag* immunised mice, the HIV Gag protein. The use of peptide pools covering Gag to measure T cell responses in mice has been described previously [@bib38], [@bib39].Table 2Percentage of NS1-expressing cells also expressing SIV Gag following infection with SIV *gag* VLP vaccinesSIVgag construct% gag positiveWT69.3 ± 0.08DX22.5 ± 0.49OPT40.2 ± 0.43gag-pol87.0 ± 0.01[^5]

*Ex vivo* ELISPOT assays measure immediate effector function and thus tend to measure effector memory T cell activity, whereas cultured ELISPOT assays measure the ability of cells to replicate and form effector cells and thus represents a measure of central memory cell activity [@bib40], [@bib41], [@bib42]. *Ex vivo* ELISPOT assays illustrated that responses induced by the WT vaccine were not significantly higher than the control VLP (*p*  = 0.092) ([Fig. 3](#fig3){ref-type="fig"}A). DX induced responses that approached significance over control VLPs (*p*  = 0.054), and OPT, Gag-pol and the HIV *gag* vaccine induced responses that were significantly higher than the control VLP (*p*  = 0.047, 0.029 and 0.039, respectively) ([Fig. 3](#fig3){ref-type="fig"}A). The OPT and Gag-pol vaccine-induced responses were comparable to those induced by the Kunjin HIV-1 *gag* VLP vaccine tested under the same conditions ([Fig. 3](#fig3){ref-type="fig"}A). Using the cultured ELISPOT assay, WT and OPT failed to produce significant responses over the controls ([Fig. 3](#fig3){ref-type="fig"}B). The Gag-pol construct induced significantly higher responses than WT (*p*  = 0.015), whereas DX (due to the very high mouse to mouse variation in this group, ranging from 2688 to 17,000 spots) did not reach significance over WT using the Median test (although it did reach asymptotic significance using the Mann--Whitney test, *p*  = 0.034). DX and Gag-pol vaccines also induced responses comparable to those induced by HIV-1 *gag* VLP vaccination ([Fig. 3](#fig3){ref-type="fig"}B). Pool 3 dominated the HIV-1 Gag responses ([Fig. 3](#fig3){ref-type="fig"}B) as this pool contains the immunodominant AMQMLKETI epitope [@bib11].Fig. 3T cells responses induced after immunisation with Kunjin-SIVmac239 *gag* VLP vaccines. (A) Measurement of Gag-specific responses by *ex vivo* ELISPOT assays. BALB/c mice (*n* = 3 or 4 per group) were immunised twice with 10^6^ IU of each of the indicated Kunjin VLP vaccines. There were two control groups, one received 10^6^ IU of a control VLP encoding an irrelevant antigen (control VLP) and the other received no vaccination (control naïve). Ten weeks after the second immunisation, the mice were sacrificed and the splenocytes were assayed for Gag-specific T cell responses by *ex vivo* IFNγ ELISPOT using six pools of overlapping peptides spanning either the SIV Gag protein for SIV *gag* vaccinated animals, or the HIV-1 Gag protein for HIV-1 *gag* vaccinated animals. Error bars illustrate the variation in responses to each pool. (B) Measurement of Gag-specific responses by cultured IFNγ ELISPOT assays. The splenocytes from the animals described in (A) were also cultured for 6 days with the pooled SIV or HIV Gag peptides, prior to the ELISPOT assay. (C) Measurement of NS3-specific responses by *ex vivo* IFNγ ELISPOT assays. The splenocytes from the animals described in (A) were also used in an *ex vivo* ELISPOT assays using the NS3 CD8 T cell peptide epitope, GYISTRVEL. (D) Measurement of NS3-specific responses by cultured IFNγ ELISPOT assays. The splenocytes from the animals described in (A) were cultured for 6 days with GYISTRVEL peptide prior to an ELISPOT assay using the same peptide.

3.3. Vector-specific CD8 T cell induction by Kunjin replicon VLP vaccines {#section0060}
-------------------------------------------------------------------------

Spaulding et al. identified a region in Dengue virus NS3, which represents a dominant CD8 T cell epitope [@bib43]. We have confirmed that the homologous region (^299^GYISTRVEL^207^) in Kunjin virus NS3, which contains a substitution (M to L) in the last amino acid, also represents a dominant CD8 T cell epitope for Kunjin replicon vaccines (data not shown). To analyse the levels of anti-vector CD8 T cell responses for the different vaccines shown in [Fig. 3](#fig3){ref-type="fig"}A and B, ELISPOT assays using the GYISTRVEL peptide epitope (at 10 μg/ml) were undertaken. *Ex vivo* IFNγ ELISPOT analysis showed that responses ranged from ≈400 to 1000 spots/10^6^ splenocytes ([Fig. 3](#fig3){ref-type="fig"}C). Cultured IFNγ ELISPOT analysis showed a range of ≈2000--5000 spots/10^6^ splenocytes for all the vectors except DX, which gave a large mean response in excess of 40,000 spots/10^6^ splenocytes ([Fig. 3](#fig3){ref-type="fig"}D). The very large response for DX might be due to the large number of VLPs not expressing Gag present in the DX preparation ([Table 2](#tbl2){ref-type="table"}). These results illustrate that flavivirus replicon-based vectors, like other vector systems [@bib44], [@bib45], also induce CD8 T cell responses specific for vector proteins.

3.4. Insert stability {#section0065}
---------------------

We and others [@bib46] have noted that flavivirus VLPs can lose expression of certain inserted genes. To investigate to what extent the different SIV *gag* VLP vaccines suffered from this problem, Vero cells were infected with VLPs and dual-labelled with anti-Kunjin NS1 and anti-Gag antibodies. For WT and Gag-pol the majority of VLP-infected cells expressed both NS1 and Gag, however, for DX and OPT only about 22% and 40% of NS1 positive cells, respectively, also expressed Gag ([Table 2](#tbl2){ref-type="table"}). For the HIV *gag* VLPs this value was \>90% (data not shown). The DX and OPT constructs contained RNA- and codon-optimised genes, perhaps suggesting that altering the coding sequence somehow reduces the stability of these inserted genes in the Kunjin replicon constructs. The *in vitro* transcribed RNA used to transfect the packaging cells did not contain any detectable truncated replicon RNA species ([Fig. 4](#fig4){ref-type="fig"}A) indicating that these insert deletion events likely occurred during VLP manufacture. Gene deletion events from flavivirus vectors have not been extensively studied. To gain some insight into the process, RNA from WT and DX VLP-infected cells was analysed by RT-PCR using primers flanking the SIV *gag* gene insert. The full-length gene is visible at ≈2000 bp, with shorter PCR products evident in both WT and DX infected cells. Gene deletions in WT and DX appear to be different, with DX showing a major band at ≈180 bp ([Fig. 4](#fig4){ref-type="fig"}B, lane 3). A band of the same size was also observed in samples from OPT-infected cells (data not shown). This ≈180 bp fragment is actually smaller than that obtained from the empty vector ([Fig. 4](#fig4){ref-type="fig"}B, lane 4), suggesting that at least one end of the deletion must lie within the ubiquitin cloning site or the FMDV 2A protease region (see [Fig. 1](#fig1){ref-type="fig"}). Sequencing of the ≈180 bp fragment from DX illustrated that the deletion occurred 15 nucleotides past the 5′ end of the 225 nucleotide Ub sequence and 29 nucleotides past the 5′ end of the 48 nucleotide FMDV2A sequence ([Fig. 4](#fig4){ref-type="fig"}B). There are no obvious homologies between the sequences either side of the insert deletion site that would suggest strand switching or homologous recombination events.Fig. 4Analysis of insert deletions in the Kunjin SIV *gag* vaccines. (A) Non-denaturing agarose gel and ethidium bromide staining of *in vitro* transcribed RNA for the indicated constructs prior to transfection of packaging cells and VLP manufacture. Note the double-stranded DNA markers do not accurately illustrate the size of the transcribed single-stranded RNA species, which are about 10.5 kb. (B) Vero cells were infected with WT (lane 2), DX (lane 3), empty VLPs (lane 4) or nothing (lane 5) and RT-PCR performed on extracted RNA using primers flanking the multiple cloning site region into which the *gag* genes were inserted for the former two constructs. Lane 1 shows the markers and lane 6 no template control. (C) Sequencing of the ≈180 bp fragment from DX transfected cells. The insert deletion is schematically represented with the sequence either side of the insert deletion site given beneath.

3.5. Protection assays {#section0070}
----------------------

Recombinant vaccinia viruses encoding HIV-1 antigens have been used extensively as surrogate viral challenge models in mice to assess protective immune responses induced by different HIV-1 vaccines [@bib11], [@bib47]. We determined whether two recombinant vaccinia viruses, one encoding SIV MNE *gag*/*po*l [@bib48] (kind gift from Dr. Shiu-Lok Hu, University of Washington, Seattle, WA) and the other SIV mac251 *gag* (EVA261, Centre for AIDS Reagents, National Institute for Biological Standards and Controls, UK) could be used in such assays. Unfortunately, although they grew well *in vitro*, both vaccinia viruses replicated very poorly in mice following i.p., intranasal or intravenous inoculations of 10^6^ or 10^7^  pfu of virus (data not shown), making them unsuitable for such assays. A vaccinia virus encoding HIV-1 *gag* was run in parallel and replicated efficiently as described previously [@bib11]. A vaccinia encoding SIVmac239 *gag* has been reported to replicate in mice [@bib1], however, this vaccinia virus has not been made publicly available, and the reason for its better replication in mice is unclear.

To develop an alternative challenge assay we generated an A20 lymphoblastic leukemia line stably expressing SIV *gag* DX fused to EGFP (A20-EGFP-SIV*gag* cells). Western blotting illustrated that these cells expressed the Gag-EGFP fusion protein, which has an expected molecular weight of ≈82 kDa ([Fig. 5](#fig5){ref-type="fig"}A). These cells were used to challenge animals ≈9 months after vaccination with the different SIV VLP vaccines. The OPT, Gag-pol and DX vaccines all provided significantly better protection than both the controls and the WT vaccine (log-rank tests all *p*  ≤ 0.006) ([Fig. 5](#fig5){ref-type="fig"}B). OPT vaccination also provided significantly better protection than DX (*p*  = 0.031), with no other comparisons showing significant differences ([Fig. 5](#fig5){ref-type="fig"}B). Mean tumour growth curves from the same experiment are shown in [Fig. 5](#fig5){ref-type="fig"}C. The percentage of mice surviving after challenge with A20-EGFP-SIV*gag* cells (0, 33, 67 and 100% for WT, DX, Gag-pol, and OPT, respectively, [Fig. 5](#fig5){ref-type="fig"}B) correlated well with the mean *ex vivo* ELISPOT data shown in [Fig. 3](#fig3){ref-type="fig"}A (100, 119, 183 and 248 spots/10^6^ splenocytes, respectively), *R* ^2^  = 0.95. A similar comparison with the cultured ELISPOT data ([Fig. 3](#fig3){ref-type="fig"}B) failed to show any correlation, *R* ^2^  = 0.04, suggesting that effector memory rather than central memory cell activity had a major role in mediating protection in this model.Fig. 5Challenge of Kunjin SIV *gag* VLP vaccinated mice with A20 cells expressing SIV mac239 Gag. (A) Western blot of A20-EGFP-SIV*gag* and parental A20 cells with anti-SIV Gag antibody (55-2F12) and anti-GFP antibody. 15 μg of total protein was loaded in each well. (B) Kaplan Meier plot of survival. Groups of mice (*n* = 4--6) were immunised twice with the indicated VLP vaccines and were then challenged ≈9 months later with A20-EGFP-SIV*gag* cells. Animals were euthanased when tumours reached 100 mm^2^. (C) Mean growth curves for the tumours from the same experiment. When an animal was euthansed a value of 100 mm^2^ was included for that animal in the mean for all subsequent time points.

4. Discussion {#section0075}
=============

Vaccines against a series of pathogens including HIV/SIV are being developed using a number of RNA-based viral vector systems. Here we describe the behaviour of four different Kunjin replicon VLP vaccines encoding SIV *gag* and show that only the Gag-pol vaccine (i) induced good levels of both effector memory and central memory T cell responses 10 weeks post-vaccination, comparable to those induced by the previously described HIV-1 *gag* Kunjin replicon VLP vaccine [@bib11], (ii) showed good levels of protection against challenge with A20 cells expressing SIV Gag ≈9 months post-vaccination, and (iii) displayed high levels of insert stability. WT and DX vaccines induced poor effector memory responses and provided poor protective activity, and OPT and DX showed high levels of insert deletion.

The potential for genetic instability for many recombinant viral vectors is well described and a range of largely vector-specific strategies have been adopted to limit the problem [@bib46], [@bib49], [@bib50], [@bib51], [@bib52], [@bib53]. In the Kunjin replicon system deletion of inserted genes appears to occur in packaging cells during VLP manufacture. For constructs with low insert stability the proportion of VLPs without inserts increases if the time between RNA transfection of the packaging line and VLP harvest is extended, and appropriate reductions of this time period can result in VLP preparations with substantially fewer empty VLPs (unpublished observation). These observations parallel those obtained for West Nile replicons where VLPs with insert deletions were also rapidly selected during serial passage of VLPs in a packaging cell line [@bib46]. In contrast, we have generated by antibiotic selection several cell lines stably transfected with recombinant Kunjin replicon vectors and these could be extensively passaged without loss of reporter gene inserts [@bib12], suggesting that insert deletion may be rare once a cell is transfected. One might speculate that insert deletion is associated with the cellular stress that leads to the cytopathic effects, which are observed in the packaging cells during VLP manufacture due to the high level of structural protein expression. Conceivably, in such stressed cells replicon RNA may gain access to the nuclear RNA splicing machinery. RNA splicing is well known to be influenced by complex RNA structure interactions, with distant RNA sequences able to regulate splicing events [@bib54]. Why DX and OPT vaccines would be more susceptible to insert deletion remains unclear, but may be associated with the loss of native RNA structures.

The DX gene was engineered to allow Rev-independent expression from DNA-based vector systems [@bib23], [@bib24], however, this did not provide significant improvements in antigen expression. The negative influence of SIV *gag* INS sequences on RNA stability and translation [@bib25], [@bib26] therefore do not appear to be significant in this system. Successful expression of wild-type SIV Gag by other vector systems where mRNA is generated in the cytoplasm (e.g. alphavirus replicons and vaccinia) also supports the view that the major influence of INS elements is on RNA export [@bib9], [@bib55]. The human codon-optimised Kunjin OPT construct did not result in significantly higher Gag expression in Vero (monkey) or BHK (hamster) cells, suggesting that tRNAs are not particularly limiting in these replicon-based expression systems when tested *in vitro*.

Why OPT and Gag-pol might provide slightly improved effector memory responses and WT and OPT induce such poor central memory responses when delivered by Kunjin replicon VLPs remains unclear, but is likely to be a reflection of multiple factors including the number of empty VLPs in the vaccine inocula, the level and length of antigen expression *in vivo*, and the level of "danger signals" induced by the replicating replicon RNA. The better memory responses induced by the Gag-pol vaccine may be due to the removal of the potentially immunosuppressive *gag*-encoded proteins [@bib29]. An alphavirus replicon SIV vaccine with these regions deleted also showed improved longevity of T cell responses over full-length *gag* constructs [@bib8]. The high (albeit variable) central memory responses induced by DX may arise from increased levels of IFNα/β produced [@bib56] as a result of the large number of empty VLPs that compromised ≈80% of the VLP inocula for this vaccine preparation ([Table 2](#tbl2){ref-type="table"}).

The A20-EGFP-SIV *gag* challenge model ([Fig. 5](#fig5){ref-type="fig"}) represents a new model for testing the effectiveness of T cell induction by SIV *gag* vaccines. This model is likely to represent a measure of SIV Gag-specific CD8 T cell activity as rejection of this tumour has previously been shown to be CD8 T cell dependent [@bib57]. Protection from this model also correlated well with the magnitude of *ex vivo* ELISPOT (effector memory) responses rather than cultured ELISPOT (central memory) responses induced by each of the Kunjin SIV vaccines. This might be expected since tumours are generally poor at stimulating the differentiation of central memory cells into effectors, so prophylactic protection would rely on effector memory cells [@bib58]. The relative importance of effector memory and/or central memory cells for prophylactic protection against HIV-1/SIV has not been extensively studied. Some evidence suggests central memory cells are more important than effector memory cells [@bib59], whereas others have argued that effector activity early in infection (when effector memory T cells would be most active) is important for protection [@bib60] and for slowing progression to AIDS [@bib61].

In summary we describe here a Kunjin replicon SIV Gag-pol VLP vaccine, which showed high insert stability, good induction of effector and central memory responses, and good protection against a model challenge. Other SIV *gag* vaccines failed in one or more of these criteria, illustrating that antigen construction and the insert\'s nucleotide sequences can have unforeseen consequences for the performance of these RNA replicon vectors.
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